NO914541L - Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner - Google Patents
Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteinerInfo
- Publication number
- NO914541L NO914541L NO91914541A NO914541A NO914541L NO 914541 L NO914541 L NO 914541L NO 91914541 A NO91914541 A NO 91914541A NO 914541 A NO914541 A NO 914541A NO 914541 L NO914541 L NO 914541L
- Authority
- NO
- Norway
- Prior art keywords
- muteins
- muteines
- necrose
- factor
- procedure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90810901 | 1990-11-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO914541D0 NO914541D0 (no) | 1991-11-20 |
NO914541L true NO914541L (no) | 1992-05-22 |
Family
ID=8205969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO91914541A NO914541L (no) | 1990-11-21 | 1991-11-20 | Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner |
Country Status (17)
Country | Link |
---|---|
US (2) | US5422104A (fi) |
EP (1) | EP0486908A3 (fi) |
JP (1) | JPH06256395A (fi) |
AR (1) | AR245783A1 (fi) |
AU (1) | AU655948B2 (fi) |
CA (1) | CA2055168A1 (fi) |
FI (1) | FI915379A (fi) |
HU (1) | HUT62034A (fi) |
IE (1) | IE914035A1 (fi) |
IL (1) | IL100062A0 (fi) |
MC (1) | MC2300A1 (fi) |
MX (1) | MX9102110A (fi) |
NO (1) | NO914541L (fi) |
NZ (1) | NZ240595A (fi) |
PT (1) | PT99560A (fi) |
UY (1) | UY23327A1 (fi) |
ZA (1) | ZA919035B (fi) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK376492A3 (en) * | 1992-04-02 | 1995-06-07 | Hoffmann La Roche | Tnf - muteins and method of their production |
CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
US7070771B1 (en) | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
EP1069917A4 (en) * | 1998-03-20 | 2005-02-09 | Genzyme Corp | NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME |
ATE329610T1 (de) * | 2000-02-16 | 2006-07-15 | Genentech Inc | Anti-april antikörper und hybridomazellen |
US7687461B2 (en) * | 2000-03-02 | 2010-03-30 | Xencor, Inc. | Treatment of TNF-α related disorders with TNF-α variant proteins |
US7446174B2 (en) | 2001-03-02 | 2008-11-04 | Xencor, Inc. | Protein based TNF-α variants for the treatment of TNF-α related disorders |
US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
US7056695B2 (en) | 2000-03-02 | 2006-06-06 | Xencor | TNF-α variants |
US7662367B2 (en) | 2000-03-02 | 2010-02-16 | Xencor, Inc. | Pharmaceutical compositions for the treatment of TNF-α related disorders |
US7244823B2 (en) | 2000-03-02 | 2007-07-17 | Xencor | TNF-alpha variants proteins for the treatment of TNF-alpha related disorders |
US20070172449A1 (en) * | 2000-03-02 | 2007-07-26 | Xencor, Inc. | TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS |
US6579522B1 (en) | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
US20050070689A1 (en) * | 2001-08-03 | 2005-03-31 | Genentech, Inc. | Taci and br3 polypeptides and uses thereof |
US20030086903A1 (en) * | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
WO2004011611A2 (en) * | 2002-07-25 | 2004-02-05 | Genentech, Inc. | Taci antibodies and uses thereof |
US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
CA2526402A1 (en) * | 2003-06-05 | 2005-01-20 | Genentech, Inc. | Blys antagonists and uses thereof |
US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
EP1687032B1 (en) * | 2003-11-14 | 2010-02-24 | Genvec, Inc. | Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc). |
TW200526780A (en) * | 2004-01-06 | 2005-08-16 | Hayashibara Biochem Lab | TNF antagonists and TNF inhibitors comprising the same as the active ingredient |
EP1598075A1 (en) * | 2004-05-21 | 2005-11-23 | LEK Pharmaceuticals d.d. | Process for the isolation and / or purification of proteins |
GB0425972D0 (en) | 2004-11-25 | 2004-12-29 | Celltech R&D Ltd | Biological products |
JP2008526889A (ja) * | 2005-01-10 | 2008-07-24 | リサーチ ディベロップメント ファウンデーション | 癌治療のための標的化キメラ分子 |
CA2629306A1 (en) * | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
WO2008127515A1 (en) * | 2007-03-01 | 2008-10-23 | Cytologic, Inc. | Compositions and method for enhancing immune responses in mammals |
US11535673B2 (en) * | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
WO2014124134A1 (en) | 2013-02-07 | 2014-08-14 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
EP3139955B1 (en) | 2014-04-30 | 2024-03-20 | President and Fellows of Harvard College | Fusion proteins for treating cancer and related methods |
MX2019005242A (es) | 2016-11-09 | 2019-09-10 | Philogen Spa | Inmunoconjugados mutantes de interleucina-2 y de factor de necrosis tumoral. |
AU2021332460A1 (en) | 2020-08-27 | 2023-04-06 | Enosi Therapeutics Corporation | Methods and compositions to treat autoimmune diseases and cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
GR851626B (fi) * | 1984-07-05 | 1985-11-26 | Genentech Inc | |
EP0251037B1 (en) * | 1986-06-20 | 1994-06-15 | Dainippon Pharmaceutical Co., Ltd. | Novel human TNF polypeptide mutants and DNAs encoding said mutants |
JPH07106158B2 (ja) * | 1986-12-04 | 1995-11-15 | サントリー株式会社 | 抗腫瘍活性を有する新規ポリペプチドおよびその製造法 |
WO1988006625A2 (en) * | 1987-02-26 | 1988-09-07 | Cetus Corporation | Arginine-depleted human tumor necrosis factor |
JPS63291590A (ja) * | 1987-05-25 | 1988-11-29 | Teijin Ltd | 新規生理活性ポリペプチド |
DE3843534A1 (de) * | 1988-12-23 | 1990-07-12 | Basf Ag | Neue tnf-polypeptide |
-
1991
- 1991-11-08 CA CA002055168A patent/CA2055168A1/en not_active Abandoned
- 1991-11-11 EP EP19910119128 patent/EP0486908A3/en not_active Withdrawn
- 1991-11-14 NZ NZ240595A patent/NZ240595A/en unknown
- 1991-11-14 FI FI915379A patent/FI915379A/fi not_active Application Discontinuation
- 1991-11-14 ZA ZA919035A patent/ZA919035B/xx unknown
- 1991-11-15 IL IL100062A patent/IL100062A0/xx unknown
- 1991-11-15 AU AU87915/91A patent/AU655948B2/en not_active Ceased
- 1991-11-15 JP JP3300863A patent/JPH06256395A/ja active Pending
- 1991-11-18 MX MX9102110A patent/MX9102110A/es unknown
- 1991-11-18 MC MC912217A patent/MC2300A1/xx unknown
- 1991-11-18 HU HU913595A patent/HUT62034A/hu unknown
- 1991-11-19 AR AR91321196A patent/AR245783A1/es active
- 1991-11-19 UY UY23327A patent/UY23327A1/es not_active IP Right Cessation
- 1991-11-20 NO NO91914541A patent/NO914541L/no unknown
- 1991-11-20 US US07/794,400 patent/US5422104A/en not_active Expired - Fee Related
- 1991-11-20 PT PT99560A patent/PT99560A/pt not_active Application Discontinuation
- 1991-11-20 IE IE403591A patent/IE914035A1/en not_active Application Discontinuation
-
1995
- 1995-03-01 US US08/397,470 patent/US5652353A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IE914035A1 (en) | 1992-06-03 |
EP0486908A3 (en) | 1992-11-19 |
AU655948B2 (en) | 1995-01-19 |
HU913595D0 (en) | 1992-01-28 |
US5422104A (en) | 1995-06-06 |
IL100062A0 (en) | 1992-08-18 |
JPH06256395A (ja) | 1994-09-13 |
FI915379A (fi) | 1992-05-22 |
CA2055168A1 (en) | 1992-05-22 |
ZA919035B (en) | 1992-08-26 |
NZ240595A (en) | 1994-09-27 |
AU8791591A (en) | 1992-05-28 |
US5652353A (en) | 1997-07-29 |
UY23327A1 (es) | 1992-05-19 |
HUT62034A (en) | 1993-03-29 |
AR245783A1 (es) | 1994-02-28 |
EP0486908A2 (en) | 1992-05-27 |
MX9102110A (es) | 1992-07-08 |
MC2300A1 (fr) | 1993-09-06 |
NO914541D0 (no) | 1991-11-20 |
PT99560A (pt) | 1992-10-30 |
FI915379A0 (fi) | 1991-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO914541L (no) | Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner | |
NO931141L (no) | Tnf-muteiner | |
DK75694A (da) | Tumornecrosefaktor og derivater og mutantformer deraf, fremgangsmåde til fremstilling deraf, DNA som koder derfor, replicerbar udtrykkelsesvektor indeholdende DNA'en og celle transformeret dermed samt præparater omfattende tumornecrosefaktoren | |
GR3024263T3 (en) | Methods and deoxyribonucleic acid for the preparation of tissue factor protein | |
DK209088D0 (da) | Medicinpraeparater, deres fremstilling og anvendelse | |
CA2185352A1 (en) | Novel muteins of ifn-.beta. | |
DK0382019T3 (da) | Anvendelse af 5-methyltetrahydrofolsyre, af 5-formyltetrahydrofolsyre og af deres farmaceutisk acceptable salte til fremstilling af farmaceutiske præparater med reguleret frigivelse egnet til anvendelse ved terapi af depressive forstyrrelser, og således fremstillede farmaceutiske præparater | |
BR9907259A (pt) | Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso | |
JO1365B1 (en) | Laoxy repo nucleic polypeptide acid has a physiological activity on humans and includes a basic sequence for the coded arrangement of the said polypeptide and a method for producing this for polypeptide and the pharmacological composition included. | |
DE59010908D1 (de) | TNF-bindende Proteine | |
DE69027865D1 (de) | ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN | |
DK0572688T3 (da) | Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi | |
NO915084L (no) | Fremgangsmaate ved fremstilling av human interleukin-5 receptor | |
NO943288L (no) | Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer | |
ATE187493T1 (de) | Gp75 als tumorimpfstoff gegen melanome | |
WO1988006625A3 (en) | Arginine-depleted human tumor necrosis factor | |
DK0564461T3 (da) | Anvendelse af antistoffer mod TNF eller fragmenter afledt deraf og xanthinderivater til kombinationsterapi samt præparater dertil | |
YU60199A (sh) | Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji | |
SE8402199L (sv) | Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist | |
DE68914397D1 (de) | Menschliches Lymphotoxin. | |
DK164885D0 (da) | ''humane phenylalaninhydroxylase cdna kloner, humane chromosomale phenylalaninhydroxylasegenkloner og fragmenter deraf, fremgangsmaade til fremstilling deraf og deres anvendelse ved diagnosticering af klassisk phenylketonuri'' | |
RU93005356A (ru) | Tnf-мутеин | |
DK314587D0 (da) | 1,4-dihydropyridinderivater, fremgangsmaade til deres fremstilling og laegemidler, der indeholder disse forbindelser | |
YU182791A (sh) | Tnf-muteini | |
NO20005321L (no) | Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette |